Evidence map›Paper›PMID 38741145›Full record

ArticleHereditary cancer in clinical practice2024

The risk of skin cancer in women who carry BRCA1 or BRCA2 mutations.

Steven A Narod, Kelly Metcalfe, Amy Finch, An-Wen Chan, Susan Randall Armel, Amber Aeilts, Andrea Eisen, Beth Karlan, Louise Bordeleau, Nadine Tung and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hereditary cancer in clinical practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Skin cancer risk in hereditary mixed cancer syndromes.Hereditary cancer in clinical practice · 2025
    Review
  4. Mapping of the hSOX10 protein interactome in human melanoma.bioRxiv : the preprint server for biology · 2025
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Steven A NarodWomen's College Research Institute, Women's College Hospital, 76 Grenville St, M5S 1B1, Toronto, ON, Canada. steven.narod@wchospital.ca.
Kelly MetcalfeWomen's College Research Institute, Women's College Hospital, 76 Grenville St, M5S 1B1, Toronto, ON, Canada.
Amy FinchWomen's College Research Institute, Women's College Hospital, 76 Grenville St, M5S 1B1, Toronto, ON, Canada.
An-Wen ChanWomen's College Research Institute, Women's College Hospital, 76 Grenville St, M5S 1B1, Toronto, ON, Canada.
Susan Randall ArmelPrincess Margaret Hospital, Familial Cancer Clinic, University Health Network, Toronto, ON, Canada.
Amber AeiltsDivision of Human Genetics, Comprehensive Cancer Center, the Ohio State University Medical Center, Columbus, OH, USA.
Andrea EisenOdette Cancer Center, Toronto, ON, Canada.
Beth KarlanDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Louise BordeleauDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Nadine TungBeth Israel Deaconess Medical Center, Boston, MA, USA.
William D FoulkesProgram in Cancer Genetics, Department of Oncology and Human Genetics, McGill University, Montréal, QC, Canada.
Susan L NeuhausenDepartment of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA.
Charis EngGenomic Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.
Olufunmilayo OlopadeDepartment of Medicine and Human Genetics, University of Chicago, Chicago, IL, USA.
Dana ZakalikCancer Genetics Program, Beaumont Hospital, Royal Oak, MI, USA.
Fergus CouchDivision of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Carey CullinaneMemorialCare Long Beach Medical Center, Long Beach, USA.
Tuya PalDivision of Genetics, Department of Medicine, Vanderbilt University Medical Centre and Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
Ping SunWomen's College Research Institute, Women's College Hospital, 76 Grenville St, M5S 1B1, Toronto, ON, Canada.
Joanne KotsopoulosWomen's College Research Institute, Women's College Hospital, 76 Grenville St, M5S 1B1, Toronto, ON, Canada.
Hereditary Breast Cancer Clinical Research Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt has not been clearly established if skin cancer or melanoma are manifestations of BRCA1 or BRCA2 mutation carrier status. Estimating the risk of skin cancer is an important step towards developing screening recommendations.

methodsWe report the findings of a prospective cohort study of 6,207 women from North America who carry BRCA1 or BRCA2 mutations. Women were followed from the date of baseline questionnaire to the diagnosis of skin cancer, to age 80 years, death from any cause, or the date of last follow-up.

resultsDuring the mean follow-up period of eight years, 3.7% of women with a BRCA1 mutation (133 of 3,623) and 3.8% of women with a BRCA2 mutation (99 of 2,584) reported a diagnosis of skin cancer (including both keratinocyte carcinomas and melanoma). The cumulative risk of all types of skin cancer from age 20 to 80 years was 14.1% for BRCA1 carriers and 10.7% for BRCA2 carriers. The cumulative risk of melanoma was 2.5% for BRCA1 carriers and 2.3% for BRCA2 carriers, compared to 1.5% for women in the general population in the United States. The strongest risk factor for skin cancer was a prior diagnosis of skin cancer.

conclusionThe risk of non-melanoma skin cancer in women who carry a mutation in BRCA1 or BRCA2 is similar to that of non-carrier women. The risk of melanoma appears to be slightly elevated. We suggest that a referral to a dermatologist or primary care provider for BRCA mutation carriers for annual skin examination and counselling regarding limiting UV exposure, the use of sunscreen and recognizing the early signs of melanoma might be warranted, but further studies are necessary.

Indexed as

Basal cell carcinomaBRCA1BRCA2MelanomaSkin cancer

Identifiers

PMID38741145
PMCPMC11089770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.